Literature DB >> 23093252

The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer.

Klaus Pantel1, Catherine Alix-Panabières.   

Abstract

Miyamoto and colleagues present data that prostate-specific antigen/prostate-specific membrane antigen (PSA/PSMA)-based measurements of androgen receptor (AR) signaling in circulating tumor cells (CTC) enable real-time quantitative monitoring of intratumoral AR signaling. This finding indicates that measuring AR signaling within CTCs may help to guide therapy in metastatic prostate cancer and highlights the use of CTCs as liquid biopsy. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23093252     DOI： 10.1158/2159-8290.CD-12-0432

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  17 in total

Review 1.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

2.  Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Nathalie Dorner; Ursula Kühs; Stefan Aufderklamm; Steffen Rausch; Simone Bier; Johannes Mischinger; Doreen Schellbach; Siegfried Hauch; Natalie Feniuk; Jens Bedke; Georgios Gakis; Arnulf Stenzl; Christian Schwentner
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

3.  Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.

Authors:  M Thalgott; M M Heck; M Eiber; M Souvatzoglou; G Hatzichristodoulou; V Kehl; B J Krause; B Rack; M Retz; J E Gschwend; U Andergassen; R Nawroth
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-24       Impact factor: 4.553

Review 4.  [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].

Authors:  E Dahl; V Kloten
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

5.  Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.

Authors:  Mark Thalgott; Brigitte Rack; Matthias Eiber; Michael Souvatzoglou; Matthias M Heck; Caroline Kronester; Ulrich Andergassen; Victoria Kehl; Bernd J Krause; Jurgen E Gschwend; Margitta Retz; Roman Nawroth
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

Review 6.  Dynamic changes in numbers and properties of circulating tumor cells and their potential applications.

Authors:  Ju-Yu Tseng; Chih-Yung Yang; Shu-Ching Liang; Ren-Shyan Liu; Jeng-Kai Jiang; Chi-Hung Lin
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

Review 7.  When Prostate Cancer Circulates in the Bloodstream.

Authors:  Virginie Vlaeminck-Guillem
Journal:  Diagnostics (Basel)       Date:  2015-10-29

8.  Microfluidic chip for graduated magnetic separation of circulating tumor cells by their epithelial cell adhesion molecule expression and magnetic nanoparticle binding.

Authors:  P Stephen Williams; Lee R Moore; Powrnima Joshi; Mark Goodin; Maciej Zborowski; Aaron Fleischman
Journal:  J Chromatogr A       Date:  2020-12-17       Impact factor: 4.759

9.  Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Authors:  Chen Shao; Chun-Peng Liao; Peizhen Hu; Chia-Yi Chu; Lei Zhang; Matthew H T Bui; Christopher S Ng; David Y Josephson; Beatrice Knudsen; Mourad Tighiouart; Hyung L Kim; Haiyen E Zhau; Leland W K Chung; Ruoxiang Wang; Edwin M Posadas
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.

Authors:  Arun Satelli; Izhar Singh Batth; Zachary Brownlee; Christina Rojas; Qing H Meng; Scott Kopetz; Shulin Li
Journal:  Sci Rep       Date:  2016-07-01       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.